MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
AcelRx Pharmaceuticals Total Current Liabilities 2011-2026 | ACRX
Annual Total Current Liabilities AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.81 M | 2.65 M | 4.51 M | 13.8 M | 18.5 M | 17.6 M | 13.6 M | 15.9 M | 13.7 M | 10.2 M | 12.8 M | 13.7 M | 6.87 M | 14.3 M | 7.84 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 M | 2.65 M | 11.3 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
128 M | $ 19.21 | -3.37 % | $ 123 M | USA |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.0 | 2.63 % | $ 108 M |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
China Pharma Holdings
CPHI
|
7.4 M | $ 0.63 | -1.56 % | $ 2.7 M |  China |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
651 M | $ 8.23 | -1.79 % | $ 421 M | USA |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.17 | 2.26 % | $ 44.6 M | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
4.3 B | $ 5.35 | -4.12 % | $ 1.95 B | Canada |
 |
Harrow Health
HROW
|
96.3 M | $ 35.31 | -0.34 % | $ 1.3 B | USA |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
75.3 M | $ 4.03 | -6.5 % | $ 260 M | USA |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.24 | -3.03 % | $ 295 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 22.7 | -0.39 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
1.01 B | $ 10.85 | -1.36 % | $ 1.5 B | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
6.43 M | $ 6.99 | -1.55 % | $ 276 M | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
9.58 M | $ 0.96 | 2.54 % | $ 34.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.37 | -2.47 % | $ 2.94 M | USA |
 |
Solid Biosciences
SLDB
|
33.5 M | $ 7.49 | 1.49 % | $ 655 M | USA |
 |
Viatris
VTRS
|
6.75 B | $ 13.44 | -1.39 % | $ 16.1 B | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.73 | 2.37 % | $ 3.15 M | USA |
 |
Zomedica Corp.
ZOM
|
9.45 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 0.89 | -0.05 % | $ 44.4 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
4.78 M | $ 2.0 | - | $ 23.1 M | USA |
 |
Tilray
TLRY
|
433 M | $ 6.55 | 6.68 % | $ 4.05 B | Canada |